Mirtazapine

CAS 85650-52-8 17 current records 4 historicalSmall Molecule

Who holds supplier records for Mirtazapine? 17 organisations hold a current record for Mirtazapine: an active US FDA Type II Drug Master File or a CEP. A further 4 organisations have only historical (inactive) DMF filings. 14 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (11), Netherlands (2), Spain (1), China (1) and 1 other country (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Mirtazapine: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/mirtazapine

Reading the evidence

  • 17 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    11 of the 16 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 7 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (17)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Mirtazapine. Country is the organisation's recorded country, not necessarily the manufacturing site.

India11Netherlands2Spain1China1Taiwan1Country not recorded for 1
Need Mirtazapine sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (14)

Certificates of Suitability on the EDQM register for Mirtazapine, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 22 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
HETERO DRUGS LIMITED HyderabadIN
CEP 2026-399 - Rev 00
Mirtazapine, Process-II
Sept 2026—
MAHI DRUGS PRIVATE LIMITED HyderabadIN
CEP 2024-394 - Rev 00
Mirtazapine
May 2026—
MEGAFINE PHARMA PRIVATE LIMITED MumbaiIN
CEP 2024-116 - Rev 01
Mirtazapine
Apr 2026—
MAITHRI DRUGS PRIVATE LIMITED Bonthapally VillageIN
CEP 2018-225 - Rev 02
Mirtazapine, Route code "ZA"
Dec 2025Inspected Aug 2025
Sweden
MICRO LABS LIMITED BengaluruIN
CEP 2025-182 - Rev 00
Mirtazapine
Oct 2025—
MATRIX PHARMACORP PRIVATE LIMITED Sangareddy DistrictIN
CEP 2019-127 - Rev 04
Mirtazapine, Process-II
Sept 2025—
APITORIA PHARMA PRIVATE LIMITED HyderabadIN
CEP 2007-062 - Rev 05
Mirtazapine
Aug 2025—
NEULAND LABORATORIES LIMITED HyderabadIN
CEP 2008-243 - Rev 06
Mirtazapine
Aug 2025—
TAPI NL B.V. AmsterdamNL
CEP 2008-141 - Rev 04
Mirtazapine
Jul 2025—
ZHEJIANG LIAOYUAN PHARMACEUTICAL CO., LTD. Duqiao TownCN
CEP 2020-158 - Rev 02
Mirtazapine, Anhydrous
May 2025—
MEGAFINE PHARMA (P) LIMITED MumbaiIN
R1-CEP 2008-214 - Rev 03
Mirtazapine, Hemihydrate
Jan 2023—
ASPEN OSS B.V. OssNL
R1-CEP 2010-016 - Rev 03
Mirtazapine
Dec 2022—
SUN PHARMACEUTICAL INDUSTRIES LIMITED MumbaiIN
R1-CEP 2010-293 - Rev 00
Mirtazapine
Apr 2018—
Medichem, S.A. Sant Joan DespíES
R1-CEP 2007-178 - Rev 00
Mirtazapine
Sept 2013—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (4)

Organisations whose Type II DMFs for Mirtazapine are no longer active. These show a past filing, not current supply.

Show all 4 historical records
  • MYLAN LABORATORIES LTD
    Inactive DMF 17521 · filed Jul 2004
  • Italy · Inactive DMF 16014 · filed Jun 2002
  • Japan · Inactive DMF 15300 · filed Feb 2001
  • DIOSYNTH BV
    Inactive DMF 8357 · filed Aug 1989

Overview

Mirtazapine is an atypical antidepressant with noradrenergic and specific serotonergic activity. It is commonly used to treat major depressive disorder and is known for its sedative effects.

Chemical identity

IUPAC name
5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene
Canonical SMILES
CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
InChIKey
RONZAEMNMFQXRA-UHFFFAOYSA-N
Synonyms
Remeron API, 6-azamianserin, avanza, mirataz, mirtazapin, mirtazapine anhydrous, mirtazapine, (±)-, norset, org 3770, org-3770, promyrtil, remeron

Therapeutic areas

DepressionAnxiety DisordersInsomnia

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Mirtazapine?

17 organisations hold an active US FDA Type II Drug Master File or a CEP for Mirtazapine: Neuland Laboratories Limited (India), APITORIA PHARMA PRIVATE LTD (India), MAITHRI DRUGS PRIVATE LTD (India), MEGAFINE PHARMA P LTD (India), ASPEN OSS BV (Netherlands), Hetero Drugs Limited (India), MAHI DRUGS PRIVATE LIMITED (India) and MATRIX PHARMACORP PRIVATE LTD (India), and 9 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Mirtazapine Drug Master Files are active?

Neuland Laboratories Limited (DMF 16007, 24022), APITORIA PHARMA PRIVATE LTD (DMF 16490, 41329), MAITHRI DRUGS PRIVATE LTD (DMF 31322, 37013), MEGAFINE PHARMA P LTD (DMF 20570, 23003), ASPEN OSS BV (DMF 10457), Hetero Drugs Limited (DMF 38341), MAHI DRUGS PRIVATE LIMITED (DMF 40203) and MATRIX PHARMACORP PRIVATE LTD (DMF 19369) and 8 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Mirtazapine records mean?

4 organisations have only inactive Type II DMFs for Mirtazapine. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Mirtazapine have a European Certificate of Suitability?

Yes. 14 organisations hold a valid CEP for Mirtazapine on the EDQM register, including HETERO DRUGS LIMITED Hyderabad (IN), MAHI DRUGS PRIVATE LIMITED Hyderabad (IN), MEGAFINE PHARMA PRIVATE LIMITED Mumbai (IN), MAITHRI DRUGS PRIVATE LIMITED Bonthapally Village (IN), MICRO LABS LIMITED Bengaluru (IN) and MATRIX PHARMACORP PRIVATE LIMITED Sangareddy District (IN) and 8 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

How do I qualify a Mirtazapine supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Mirtazapine?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.